



16 March 2020

10:15-15:00

Workshop

Ready for Translation?

The role of supporting preclinical evidence in justifying phase I/II trials with somatic genome editing

KEY NOTE

Philip John (P.J.) Brooks

Working Group Coordinator, NIH Common Fund program on Somatic Cell Genome Editing

> NCATS Program Director, Office of Rare Diseases Research

Program

10:15 Intro: Daniel Strech, BIH QUEST Center/Charité

10:30 Reporting of robustness criteria in results publications for preclinical genome editing, Merlin Bittlinger, BIH QUEST Center/Charité

10:45 Reporting of supporting preclinical evidence in investigator brochures (IBs) for phase I/II trials, Susanne Wieschowski, Hannover Medical School

11:00 KEY NOTE: The NIH/NCATS funding requirements for confirmation in preclinical somatic genome editing: Rationale and experiences, PJ Brooks, NIH/NCATS

11:45 The new BMBF funding scheme for confirmatory preclinical studies & and the accompanying DECIDE project, Ulf Tölch, BIH QUEST Center/Charité

12:00 Lunch

13:15 Open discussion / Future directions What should we expect from supporting evidence for phase I/II trials?

14:45 Summary / Outlook

15:00 End of Workshop

Venue

BIH QUEST Center Anna-Louisa-Karsch-Str. 2, 5th floor 10178 Berlin

Getting there

S-Bahn, stop Hackescher Markt see also:

https://www.bihealth.org/en/about-us/contact/

Contact & registration

Registration is required via e-mail by 10th March to:

konstanze.scheurer@charite.de

Tel. + 30 450 543676

https://www.bihealth.org/en/

Funding

The workshop is funded by the BMBF-sponsored project GEENGOV-Governance of Biomedical Genome Editing **GEFÖRDERT VOM**





